[go: up one dir, main page]

EP4069244A4 - Verwendung von reboxetin zur behandlung von störungen des nervensystems - Google Patents

Verwendung von reboxetin zur behandlung von störungen des nervensystems Download PDF

Info

Publication number
EP4069244A4
EP4069244A4 EP20895126.9A EP20895126A EP4069244A4 EP 4069244 A4 EP4069244 A4 EP 4069244A4 EP 20895126 A EP20895126 A EP 20895126A EP 4069244 A4 EP4069244 A4 EP 4069244A4
Authority
EP
European Patent Office
Prior art keywords
reboxetine
nervous system
system disorders
treat nervous
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20895126.9A
Other languages
English (en)
French (fr)
Other versions
EP4069244A1 (de
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of EP4069244A1 publication Critical patent/EP4069244A1/de
Publication of EP4069244A4 publication Critical patent/EP4069244A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20895126.9A 2019-12-03 2020-11-30 Verwendung von reboxetin zur behandlung von störungen des nervensystems Pending EP4069244A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (2)

Publication Number Publication Date
EP4069244A1 EP4069244A1 (de) 2022-10-12
EP4069244A4 true EP4069244A4 (de) 2023-12-20

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20895126.9A Pending EP4069244A4 (de) 2019-12-03 2020-11-30 Verwendung von reboxetin zur behandlung von störungen des nervensystems

Country Status (12)

Country Link
EP (1) EP4069244A4 (de)
JP (1) JP2023504685A (de)
KR (1) KR20220108122A (de)
CN (1) CN114746097A (de)
AU (2) AU2020395082A1 (de)
BR (1) BR112022010677A2 (de)
CA (1) CA3163505A1 (de)
CO (1) CO2022007507A2 (de)
CR (1) CR20220247A (de)
IL (1) IL293536A (de)
MX (1) MX2022006630A (de)
PE (1) PE20230181A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2247572T3 (es) * 1999-07-01 2006-03-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar las cefaleas migrañosas.
PL197983B1 (pl) * 1999-07-01 2008-05-30 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
AU2008248382B2 (en) * 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2014164969A1 (en) * 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARCIA-BORREGUERO D ET AL: "567.K Effects of reboxetine in narcolepsy-cataplexy: Preliminary findings on 14 patients", SLEEP; 15TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES; CHICAGO, ILLINOIS, USA; JUNE 05-10, 2001, ALLEN PRESS, LAWRENCE, KS, US, vol. 24, no. Abstract Supplement, 15 April 2001 (2001-04-15), pages A323 - A324, XP009531711, ISSN: 0161-8105 *
O' GORMAN CEDRIC ET AL: "SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT OF AXS-12 FOR NARCOLEPSY", SLEEP, vol. 42, no. Abstract Supplement, 1 January 2019 (2019-01-01), pages A24, XP055866024 *
SCHMIDT CHRISTIAN ET AL: "The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 308, 23 April 2016 (2016-04-23), pages 205 - 210, XP029542431, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2016.04.033 *
See also references of WO2021113163A1 *

Also Published As

Publication number Publication date
AU2020395082A1 (en) 2022-06-09
PE20230181A1 (es) 2023-02-01
BR112022010677A2 (pt) 2022-08-16
KR20220108122A (ko) 2022-08-02
CR20220247A (es) 2022-08-18
MX2022006630A (es) 2022-06-24
CN114746097A (zh) 2022-07-12
CA3163505A1 (en) 2021-06-10
IL293536A (en) 2022-08-01
JP2023504685A (ja) 2023-02-06
CO2022007507A2 (es) 2022-06-21
EP4069244A1 (de) 2022-10-12
AU2024203676A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
EP3618824A4 (de) Verwendung von n-acetylcystein zur behandlung von erkrankungen des zentralen nervensystems
EP3952982C0 (de) System zur vagusnervstimulation zur behandlung von neurodegenerativen störungen
EP2323667A4 (de) Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
EP3389725A4 (de) Zusammensetzungen und verfahren zur behandlung von erkrankungen des zentralen nervensystems
EP3139914C0 (de) Verbindungen zur behandlung von augenerkrankungen und -leiden
EP2852388A4 (de) Verbindungen und verfahren zur verwendung davon zur behandlung von neurodegenerativen erkrankungen
EP3364993A4 (de) Verfahren zur behandlung des angelman-syndroms und verwandter störungen
EP3525735A4 (de) Therapeutisches ultraschall gegen augenerkrankungen
EP3465212A4 (de) Regulierung der darmflora zur behandlung neurodegenerativer erkrankungen
EP3713558A4 (de) Aminoadamantylnitratverbindungen und ihre verwendung zur behandlung von zns-erkrankungen
EP3445451A4 (de) Zusammensetzungen und verfahren zur behandlung von durch lysosomale dysfunktion gekennzeichnete lysosomalen speicherstörungen und erkrankungen
MA41459A (fr) Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3692023A4 (de) Benzothiazolverbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
EP3955937A4 (de) Verbindungen und zusammensetzungen zur behandlung von augenkrankheiten
EP2970099A4 (de) Substituierte 3-phenylpropylaminderivate zur behandlung von augenerkrankungen und -leiden
EP2782566A4 (de) L-serin-zusammensetzungen, verfahren und verwendungen zur behandlung neurodegenerativer erkrankungen und leiden
EP3621434A4 (de) Verfahren zur behandlung von neuropsychiatrischen störungen
EP3840740A4 (de) Verbindungen zur behandlung von angeborenen glycosylierungsstörungen
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
EP3352755A4 (de) Neuartige zusammensetzungen und verfahren zur behandlung und vorbeugung von hautkrankheiten
EP2435563A4 (de) Modulation von phospholipase d zur behandlung neurodegenerativer erkrankungen
EP3471746A4 (de) Verfahren und zusammensetzung zur behandlung von krampfanfällen
EP3955926A4 (de) Verbindungen und zusammensetzungen zur behandlung von augenkrankheiten
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080135

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

A4 Supplementary search report drawn up and despatched

Effective date: 20231122

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20231116BHEP

Ipc: A61P 25/00 20060101ALI20231116BHEP

Ipc: A61P 25/24 20060101ALI20231116BHEP

Ipc: A61K 31/5375 20060101AFI20231116BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250616